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Abstract Thrombin and other mitogens regulate the expression 
of the urokinase-type plasminogen activator receptor (uPAR) 
protein and mRNA levels in bovine vascular smooth muscle cells 
(SMC). We investigated interactions between mitogens capable 
of increasing uPAR mRNA levels in SMC. Up-regulation of 
uPAR mRNA upon thrombin and basic fibroblast growth factor 
(bFGF) stimulation was preceded by a 2-3-fold transient 
increase in bFGF mRNA within 1 h. TGF-[~I did not result in 
a significant change in bFGF mRNA levels. Platelet-derived 
growth factor (PDGF) while substantially enhancing uPAR 
mRNA levels, diminished bFGF mRNA levels by 3-4-fold. Both 
thrombin and bFGF induced the message for bFGF-R 2-3-fold. 
Thrombin also provoked a 3-4-fold rise in TGF-[~I mRNA levels 
within 30 rain. In summary, on the mRNA level, we demonstrated 
both positive as well as negative feed-back mechanisms between 
different mitogens, among them bFGF revealing in addition to 
autoinduction also up-regulation of the transcript concentration 
of its own receptor. Thus, cooperation and possible amplification 
of mitogenic effects might be implicated in the fine-tuned 
regulation of uPAR mRNA in stimulated bovine aorta SMC. 
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1. Introduction 
Proliferation and migration of transformed secretory vascu- 
la~ ~ smooth muscle cells (SMC) during atherosclerotic events 
ai,., ~ believed to be under the control of several mitogens. These 
m, togens not only increase new DNA synthesis and cell num- 
ber of target cells [1], but may also promote cell invasiveness 
b) several mechanisms, including the modulation of cell sur- 
t'a~:e uPA/plasmin-mediated proteolytic activity [2]. One of the 
key components of the tissue fibrinolytic enzyme system is the 
cel  surface receptor for uPA (uPAR) which enhances plasmin 
generation by binding with high affinity to active uPA as well 
as pro-uPA, uPAR has been identified on several tumor cells, 
monocytoid U937 cells [3] and on cultured bovine aorta SMC 
[41. Several mitogens including thrombin, bFGF,  PDGF,  and 
TGF-131 were shown to produce uPAR affinity changes and 
in,-reased receptor expression [4] coinciding with increased 
ut 'AR mRNA levels on bovine vascular SMC [5]. Most of 
th~se mitogens are thought to produce their biological effects 
in cooperation with other mitogens dependent on their inter- 
a~tions with specific cell surface receptors. In this report we 
stadied possible mitogen 'crosstalk' occurring in stimulated 
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SMC and monitored in parallel changes in uPAR mRNA 
levels. 
2. Materials and methods 
2.1. Materials" 
Bovine ec-thrombin, PDGF, TGF-[31, bFGF, and all tissue culture 
reagents were obtained from vendors as outlined previously [4,5]. An 
in vitro transcription kit, pGEM vectors, and a RNA isolation kit 
were from Promega, Madison, WI. A kit for RNase protection assays 
was from Ambion, Austin, TX. [32p]UTP was obtained from NEN 
Dupont, Boston, MA. A kit for first-strand cDNA synthesis was 
purchased from BRL, Gaithersburg, MD. A plasmid isolation kit 
was obtained from Quiagen, Chlotsworth, CA. Reagents for polymer- 
ase chain reaction (PCR) were from Perkin Elmer Cetus, Norwalk, 
CT. Synthesis and purification of PCR primers were performed at 
Northwestern University, Chicago, IL. 
2.2. Cell culture 
Bovine aorta SMC were isolated, cultured and growth-arrested 
prior to stimulation as described earlier [4,5]. Stimulation at 37°C 
was performed with 40 U/ml thrombin, 20 ng/ml PDGF, 10 ng/ml 
bFGF, or 10 ng/ml TGF-[~I, concentrations chosen based on dose- 
response xperiments on uPAR expression on SMC. 
2.3. RNA isolation 
Total RNA was isolated by acid guanidinium thiocyanate-phenol- 
chloroform extraction [6]. 
2.4. Isolation of cDNA clones and subcloning 
A full-length cDNA clone for bovine uPAR was isolated from a 
bovine aorta endothelial cell cDNA library [7]. The generation of the 
bovine uPAR- and amyloid precursor protein (APP) cRNA has been 
described earlier [5]. The cDNA fragments for bovine bFGF (390 bp) 
and bovine TGF-131 (320 bp) were generated by PCR on bovine 
cDNA reverse-transcribed from total RNA, utilizing as primers 
bFGF 5': GAG GAC GGC GGC AGC GGC GCTIbFGF 3': CTG 
CCC AGG TCC TGT TTT GGG [8] and TGF-~I 5': ACC AAC 
TAC TGC TTC AGC TCC ACA GAA/TGF-~I 3': TTG CAG GAG 
CGC ACG ATC ATG [9], respectively, and subcloned into the tran- 
scription vector pGEM-4Z. Since the sequence for bovine bFGF-R is 
unknown, we designed degenerate PCR primers based on sequences 
for bFGF-R of known species counterparts [10]: bFGF-R 5': CCG 
GAA TTC GAG/A GGC TGC TTT GGG CA and bFGF-R 3' : CGC 
GGA TCC GCC AGG TCT CT/GG TGT/G ATG GA. The nucleo- 
tide sequences of the PCR-generated DNA fragments were confirmed 
by sequencing analyses. 
2.5. In vitro transcription and RNase protection assay (RPA) 
In vitro transcription and RPA were performed as described earlier 
[5]. Intensity of the signals on autoradiographs of dried gels was 
quantitatively analyzed by laser densitometry (Ultroscan XL Laser 
Densitometer, Pharmacia, Piscataway, N J). The relative abundance 
of uPAR, bFGF-, bFGF-R-, and TGF-131 mRNA was determined 
by normalizing the integrated signal from the resulting protected frag- 
ments to the integrated signal of the internal standard APP probe. 
Alternatively, original dried gels were scanned in a [~-scanner (Beta- 
scope 603 Blot Analyzer, Betagen, Mountain View, CA). The relative 
amounts are given as 'fold increase'/unstimulated control. All given 
values were obtained from three independent repeats of experiments. 
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Message levels in total RNA from unstimulated cultured SMC co- 
hybridized with the cRNA probes used in this study did not change 
significantly during the same time period. Upon stimulation of SMC 
with different mitogens we did not observe significant changes in the 
signals obtained from the internal standard APP. 
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Fig. l. Time-dependent effect of thrombin and bFGF on bFGF- 
and uPAR mRNA levels in bovine vascular SMC. A: SMC were 
exposed to thrombin (40 U/ml), total RNA isolated and RPA per- 
formed. The relative abundance of mRNA for bFGF (e), uPAR 
(B) and APP (D) measured and calculated by laser densitometry are 
outlined in Section 2. The values at each time point are given as 
'fold induction' assigning a value o f ' l '  to the message level at time 
'0'. Each value represents the mean of triplicate experiments. B: 
SMC exposed to bFGF. Methods as described above, bFGF (e), 
uPAR (B), and APP (D). 
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Fig. 2. Effect of thrombin on TGF-131- and uPAR mRNA levels in 
vascular SMC. Bovine SMC were exposed to thrombin (40 U/ml) 
and harvested at time point '0' (lane 1), 15 min (lane 2), 30 min 
(lane 3), 1 h (lane 4), 2 h (lane 5), 4 h (lane 6), and 6 h (lane 7). 
32p-labeled TGF-131-, uPAR-, and APP cRNAs were co-hybridized 
with 10 ~g of total SMC RNA overnight at 42°C. RPA were per- 
formed as described and the protected fragments (TGF-~I: 320 bp, 
uPAR: 279 bp; APP: 229 bp) electrophoresed on Tris-borate- 
EDTA/polyacrylamide/urea g ls which were dried and exposed to 
X-ray films for autoradiography. The radiolabeled TGF-I]I, uPAR, 
and APP cRNA probes are shown in lane 12. M: 32p-labeled 
Lambda HindllI, PhiX HaelII marker. 
3. Results and discussion 
There is evidence that cell invasiveness requires cell surface 
proteolytic activity, e.g., plasmin, capable of altering cell-cell 
and cell-substratum interactions. The existence of uPAR on 
vascular SMC in culture [4], which strongly resemble the 
transformed SMC phenotype, suggested that uPAR might 
be involved in SMC migration during atherosclerotic events. 
Mitogens available at the site of atherosclerotic lesions, origi- 
nating from platelets, monocytes/macrophages, endothelial 
cells, and neointimal SMC, all cells that are present within 
the atheromatous plaque, are known to regulate uPAR ex- 
pression [11]. At sites of fracture of atheromatous plaques, 
platelets accumulate setting the stage for thrombin generation 
which can initiate and propagate an intravascular thrombus 
and also act as a mitogen for adjacent cells in the vessel wall. 
Thrombin in addition to other growth factors may not work 
separately in the propagation of atheromatous plaque forma- 
tion but may act cooperatively with other growth factors 
through additive, synergistic or 'cascade-like' ffects [12]. 
In the present study on bovine vascular SMC we examined 
elevation of mRNA levels for different mitogens upon stimu- 
lation while monitoring in parallel increases in uPAR mRNA 
levels. Exposure of SMC to thrombin previously shown to 
increase uPAR mRNA levels [4] resulted in a transient 2-3- 
fold increase in bFGF message levels. Peak levels at approxi- 
mately 30 min with a rapid decline to basal levels preceded the 
rise in uPAR mRNA at 4 h (Fig. 1). This is in agreement with 
observations that thrombin provoked the appearance of 
bFGF detected in cellular lysates of vascular SMC [13] and 
fibroblasts [14], suggesting a role for bFGF in thrombin's 
mitogenic activity. It has been reported earlier that both 
thrombin but also TGF-131 enhance the expression of other 
growth factors (e.g., PDGF) in human microvascular en- 
dothelial cells and vascular SMC followed by an increase in 
growth-factor-like activity in conditioned media [15,16]. In 
addition, we also observed that thrombin induced TGF-131 
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F g. 3. Time-dependent effect of bFGF on bFGF-R mRNA levels. 
B,vine aorta SMC were exposed to bFGF (10 ng/ml). The cells 
w:re harvested at time point '0' (lane 1), 15 min (lane 2), 30 min 
(Lne 3), 1 h (lane 4), 2 h (lane 5), 4 h (lane 6), and 6 h (lane 7). 
R~IA was hybridized with a2p-labeled bFGF-R-, uPAR-, and APP 
cRNAs and RPA performed. The relative abundance of the bFGF- 
R (417 bp) and uPAR protected fragment (279 bp) were determined 
b:. scanning the gels in a 13-scanner, normalizing the cpm values to 
tl ~ e signals of interest to the signal from the internal standard APP. 
1~: 32p-labeled Lambda HindIII, PhiX HaeIII marker. 
m RNA approximately 3~,-fold within 30 min followed by a 
rt turn to basal levels within approximately 4 h (Fig. 2). 
It is known that several growth factors are capable of in- 
dacing their own message xpression in vitro. [17,18]. Indeed, 
bJ:GF produced a 2 3-fold increase in its own transcript con- 
c, ntration (Fig. 1). Basic FGF  is widely distributed and seems 
t, be implicated in cell proliferation and cell migration in 
sL.veral different pathologies including tumor growth and 
a herosclerosis [19,20]. During remodeling of the matrix, 
b~GF is mobilized as a complex with heparan sulphate pro- 
ttoglycans by the action of cell surface plasmin and subse- 
q lently binds to specific cell surface receptors [21]. The bio- 
a ,ailability of bFGF is thus directly under the control of the 
ui'A/plasmin-mediated proteolytic activity on cell surfaces 
[22]. This might suggest positive feedback mechanisms: en- 
hmced plasmin generation facilitated by increased uPAR 
nlmbers upon bFGF stimulation promotes the release of 
b~GF from the extracellular matrix [23]. Moreover, bFGF 
i~ a potent activator of SMC proliferation [24]. In contrast 
t,, bFGF,  TGF-[31, which significantly increased uPAR mes- 
s,ge levels [5], did not reveal any effect on its own message 
(,!ata not shown), an observation in contrast o other reports 
d~scribing TGF-~I autoinduction [25]. 
Increased responsiveness of transformed migratory SMC 
a~d perhaps other cell types to elevated mitogen levels neces- 
s rates the presence of sufficient numbers of available specific 
n itogen receptor sites. On cultured vascular SMC we ob- 
s~:rved that both thrombin and bFGF increased bFGF-R  
n~RNA levels 2 3-fold coinciding with increased bFGF 
nRNA.  This rise preceded the increase in uPAR mRNA lev- 
es, initially detectable at time point 4 h (Fig. 3). This is in 
a~;reement with the observation that enhanced bFGF and 
b FGF-R expression also occurs in invasive carcinoma cell 
liraes but not in non-invasive cells [26]. Moreover, thrombin 
a ; well as bFGF increased mRNA levels of the thrombin 
r,.~ceptor [5] strongly implicated in thrombin-mediated cellular 
eifects on platelets and endothelial cells. 
In PDGF stimulated SMC an unexpected ecline in bFGF 
mRNA was observed. A 34-fo ld decrease, initially detectable 
at 4 h, coincided with the rise in uPAR mRNA levels (Fig. 4). 
Although several examples of a mutual down-regulation 
among mitogens are published, including the decrease of 
bFGF's  mitogenic activity by TGF-131 [27] or the down-reg- 
ulation of TGF-131 binding to its receptor by bFGF [14], the 
relevance of the down-regulation of bFGF mRNA levels in 
SMC by higher concentrations of PDGF are unclear at this 
time. In principle, it should be noted here critically that in- 
creases in mRNA concentrations of certain proteins do not 
necessarily reflect respective changes in protein expression 
even in general this has been shown to be the case. 
The observed induction of mitogen mRNA expression in 
cultured bovine vascular SMC, data which although not nec- 
essarily reflecting similar changes on the protein levels of the 
respective mitogens, are, however, very much consistent with 
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Fig. 4. Time course of the effect of PDGF on bFGF and uPAR 
mRNA levels in bovine vascular SMC. A: SMC were exposed to 
PDGF-BB (20 ng/ml) and the cells harvested at time point '0' (lane 
1), 15 min (lane 2), 30 min (lane 3), 1 h (lane 4), 2 h (lane 5), 4 h 
(lane 6), 6 h (lane 7), 9 h (lane 8), 12 h (lane 9), 24 h (lane 10), and 
48 h (lane 11). cRNA probes for bFGF, uPAR as well as APP 
were co-hybridized and the protected fragments electrophoresed on 
Tris-borate-EDTA/polyacrylamide/urea gels which were dried and 
exposed to X-ray films for autoradiography. The radiolabeled 
bFGF-, uPAR-, and APP cRNAs are shown in lane 12. B: Value 
at each time point in Fig. 4A expressed as 'fold induction': bFGF 
(o), uPAR (B), APP (rT). 
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in situ findings that transcripts for several growth factors and 
their receptors including PDGF-B,  the [3-subunit of the 
PDGF receptor, and TGF-~I were increased in advanced 
atherosclerotic lesions. In contrast, growth-promoting mole- 
cules and their specific receptors are not expressed in SMC 
from the tunica media of normal arteries or in regions of the 
intima unaffected by atherosclerosis [28]. 
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